Q: How Idarucizumab, reversal of  Dabigatran works?


Answer: Idarucizumab is a dabigatran-specific antidote and is a humanized monoclonal antibody fragment, also called Fab.

Dabigatran is an oral anticoagulant and is a direct thrombin inhibitor. It is used as an oral therapy in patients with atrial fibrillation to prevent CVAs,  deep venous thrombosis (DVT) and pulmonary embolism (PE). It carries risk of life threatening bleeding and was avoided by many physicians as no effective reversal was available. 

In October 2015, FDA approved Idarucizumab. The recommended dose is one time IV use of 5 gram (or two pre-mix vials).